Back to Agenda
Regulatory Science Hand in Hand with Health Technology Assessment for Better Outcomes
Session Chair(s)
Karin Van Baelen, PharmD
Head, Global Regulatory Affairs
Janssen, Belgium
This session will provide insights from key stakeholders on the impact of regulatory science, pharmaceutical legislation and HTA on the effectiveness of the EU regulatory system’s ability to overcome obstacles and focus on better outcomes for patients’ health.
Speaker(s)
Is Our Regulatory System Effective? Recent Examples of Applied Regulatory Science
Hugo Hurts
Medicines Evaluation Board (MEB), Netherlands
Chair HMA Brexit Task Force; Executive Director
The Beauty of New Science - What Is Needed to Translate It into Better Outcomes? An Industry Perspective
Richard Bergström, MS
European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
Director General
How Does the Regulatory and HTA System Keep Pace with New Science? EU Commission Perspectives on the EU Pharmaceutical Framework and HTA Cooperation
Ioana-Raluca Siska, MD, PhD
European Commission, Belgium
Policy Officer, Health Technology Assessment
Have an account?